NeoGenomics : Conference Call Presentation

NeoGenomics

Investor Presentation

May 2021

Forward-Looking Statements

This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither this presentation, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to business, operations, and financial conditions of the Company. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "would," "should" and "could," and similar expressions or words, identify forward-looking statements. Although the Company believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Actual results could differ materially from those projected in the Company's forward-looking statements due to numerous known and unknown risks and uncertainties. All forward-looking statements speak only as of the date of this presentation and are qualified in their entirety by this cautionary statement. The Company undertakes no obligation to revise or update this presentation to reflect events or circumstances after the date hereof.

Non-GAAP Adjusted EBITDA

"Adjusted EBITDA" is defined by NeoGenomics as net income from continuing operations before: (i) interest expense, (ii) tax expense, (iii) depreciation and amortization expense, (iv) non-cashstock-based compensation expense, and, if applicable in a reporting period, (v) acquisition and integration related expenses, (vi) non-cash impairments of intangible assets, (vii) and other significant non-recurring or non-operating (income) or expenses, including any debt financing costs.

2

3

Our Next Step

Our Formula For Oncology Leadership is Accelerating

The Acquisition of Inivata Builds Upon Our Previous Successful Business Development

Building Strategic Scale

• Leadership in the clinical market achieved through M&A and rapid organic growth
• Demonstrated our ability to build scale - acquire, integrate and run businesses

Creating A Flywheel For Organic

Growth

Powering Platform Integration

• Built out leading pharma services business with differentiated companion diagnostic capabilities
• Launched Informatics initiative to leverage data to strengthen core businesses and provide independent revenue stream

Driving Market Leadership with

Best-in-Class Technology

• Combination of channel leadership with leading liquid biopsy platform technology - continues "One Lab" mission while accelerating growth in a massive market opportunity

Oncology Division

4

Inivata Review: One Leading Liquid Biopsy Platform with Multiple Applications

| L I Q U I D B I O P S Y P L AT F O R M

Specifically designed for liquid biopsy	Optimized for high sensitivity		Robust customizable approach
					+
	Commercialized by NeoGenomics
• 37 gene panel for advanced NSCLC		• Personalized assay / multi-tumor
• SNV, Indels, CNV and fusions		• 48 markers derived from tissue analysis
• CAP / CLIA lab		• CAP / CLIA lab from late 2020
• Medicare reimbursed test		• Turnaround time within 7 calendar days
• Turnaround time within 7 calendar days			• Sensitivity: 10ppm / 0.001VAF%
R&D Capabilities		Regulatory Capabilities		Reimbursement Capabilities

5